Medtronic (MDT) Q4 2026 Earnings Transcript

Medtronic reported Q4 revenue of $9.8 billion, up 9.9% reported and 6.6% organically, with fiscal 2026 revenue of $36.4 billion up 8.4% reported and adjusted EPS of $5.53 beating expectations. Fiscal 2027 guidance calls for 6.75%-7.25% organic revenue growth and EPS of $5.90-$6.00, despite a projected $250 million tariff headwind and about 20 bps of gross margin pressure. Growth remains broad-based, led by 78% CAS growth, 145% PFA growth, strong Hugo robotics momentum, and continued expansion in Symplicity and Altaviva, while MiniMed was spun off via IPO during the quarter.

Analysis

The core read-through is that MDT is no longer a single-product turnaround story; it is becoming a compounding installed-base and consumables story across multiple adjacencies. The second-order effect is that each incremental platform win in CAS, robotics, neuro, or renal denervation raises future recurring revenue density, which should smooth the earnings path even if headline growth lurches around from mix and launch timing. That matters because the market has historically discounted MDT as a slow, low-multiple medtech compounder; if execution holds, the multiple can rerate before the P&L fully shows it.

The bigger near-term debate is not growth, but margin quality. Tariffs and the Diabetes overhang are visible, but management is implicitly telling us those are temporary drags masking a cleaner operating model underneath: pricing discipline, cost-out, and leverage from a more focused portfolio. The risk is that investors overindex on the guided EPS bridge and miss that the real swing factor is mix—if CAS catheter pull-through and Hugo/Stealth adoption continue, the gross-margin profile should improve more in the back half than the market likely models. That creates a setup where incremental positive commercial data can drive estimate revisions faster than the full-year guide suggests.

Competitively, the likely losers are incumbents that rely on older workflows and weaker software ecosystems. In EP, MDT is trying to turn hardware into a platform lock-in game; in robotics and neurosurgery, the value shifts toward integrated workflow and digital attach, which is harder for point-solution rivals to defend. The contrarian view is that consensus may still underappreciate how much of MDT’s growth is now self-reinforcing across ecosystems—every installed base expansion raises the probability of consumable pull-through, software adoption, and cross-sell, which means growth can remain resilient even if one category decelerates modestly. The main catalyst clock is 3-6 months: upcoming procedure trends, U.S. ramp data, and any sign that post-tariff gross margin improvement is real rather than just deferred.

Key Decisions for Investors

• Long MDT into the next 1-3 quarters: use any pullbacks on tariff headlines to build a position; risk/reward favors upside if CAS/robotics attach drives even modest estimate revisions and the market re-rates the quality of growth.
• Pair trade: long MDT / short more mature single-line medtech peers with slower innovation cadence over 6-12 months; MDT has more embedded optionality from platform launches and should compound faster if execution persists.
• Buy MDT Jan-2027 call spreads on weakness: the setup is for a multiple expansion over 6-9 months as investors gain confidence in sustained above-market growth and back-half margin improvement; defined risk is attractive versus outright equity.
• For a relative value hedge, pair MDT long against a basket of companies more exposed to tariff- and mix-driven margin compression; MDT’s diversified growth and cost-out should make it a cleaner beneficiary if trade policy remains noisy.
• Reduce or avoid chasing after sharp gap-ups: the name is likely to trade on quarterly procedure data and guidance digestion, so better entry points are post-earnings fades rather than momentum highs.